Albuquerque, NM, January 18, 2014 -- Sheldon K. Jordan, PhD, President and CEO, Peptineo, announces the appointment of Eric Bachelder, PhD, to the company's Scientific Advisory Board. "We are extremely pleased that Dr. Bachelder has joined the Peptineo Scientific Advisory Board. Dr. Bachelder is recognized as an emerging scientist in the development of novel drug delivery moieties for the treatment of inflammation and other debilitating diseases. He and his colleagues were instrumental in the advancement of a new class of polymers that have implications for vaccines, antibiotics, siRNA delivery, and for other diseases with unmet therapeutic needs. We very much look forward to Dr. Bachelder's input regarding the most efficient development of our drug delivery portfolio and related peptide-based compounds," says Dr. Jordan.
Dr. Bachelder currently maintains a research appointment at the Ohio State University, Columbus, Ohio. He maintains various academic collaborations that focus on advanced immune therapies, nano- and micro-particulate carriers, and the formulation of novel polymers. Recent publications include a novel experimental vaccine for Bacillus Anthracis, encapsulation and storage of a model protein outside the pharmaceutical cold-chain with implications for vaccines, treatment therapies for infection, and development of tolerogenic vaccines. Dr. Bachelder holds degrees from Michigan State University and the University of Nebraska and has performed research at the National Institutes of Health and the University of California at Berkeley.
With an expanding portfolio of intellectual property and interdisciplinary technical expertise, Peptineo represents the new face of biotechnology and bioengineering. By employing a systems-based approach, Peptineo technical solutions involve drug delivery combinations including “tunable” nano-carriers, engineered peptides, re-formulated pharmaceuticals, and as appropriate, recombinant proteins. Additionally, Peptineo is developing technologies that will greatly enhance and accelerate the drug discovery process.
Media contact: VP of Business Development, +1 (855) FULL-BIO (385-5246)
609 Broadway Blvd NE, Albuquerque, New Mexico 87102
Website: (http://www.peptineo.com) Email: email@example.com
Source: Peptineo, LLC